Similarly, Segain et al. demonstrated that oral sodium butyrate reduced pro-inflammatory cytokine expression in CD patients by inhibiting NF-κB, suggesting a conserved anti-inflammatory mechanism across IBD subtypes [100]. The gene discussed is NFKB1; the disease is irritable bowel syndrome.